Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Gains from Investment Securities (2022 - 2024)

Bioregenx (BRGX) has 3 years of Gains from Investment Securities data on record, last reported at $19351.0 in Q1 2024.

  • For Q1 2024, Gains from Investment Securities changed N/A year-over-year to $19351.0; the TTM value through Mar 2025 reached $282722.0, up 21.9%, while the annual FY2024 figure was $47.3 million, 102.68% up from the prior year.
  • Gains from Investment Securities reached $19351.0 in Q1 2024 per BRGX's latest filing, down from $263371.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $263371.0 in Q4 2023 and bottomed at -$59400.0 in Q4 2022.
  • Average Gains from Investment Securities over 3 years is $38584.4, with a median of $19351.0 recorded in 2024.
  • The widest YoY moves for Gains from Investment Securities: up 543.39% in 2023, down 349.02% in 2023.
  • A 3-year view of Gains from Investment Securities shows it stood at -$59400.0 in 2022, then skyrocketed by 543.39% to $263371.0 in 2023, then crashed by 92.65% to $19351.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $19351.0 in Q1 2024, $263371.0 in Q4 2023, and -$50800.0 in Q3 2023.